Despite the focus on immuno-oncology right now, Deciphera has data showing there is still plenty to talk about when it comes to kinase inhibitors.
The partners want to improve on blunt force of the initial CAR-Ts by creating more controllable therapies.
TP Therapeutics netted $80 million and a new CEO as it looks to move its lead candidate in drug-resistant tumors into phase 2 early next year.
A Tufts University-led team has developed 3D models of the central nervous system that might prove useful for drug discovery.
Amgen has invested $66 million (£50 million) into portable genome sequencer developer Oxford Nanopore.
In May 2017, Sosei invested £35 million in MiNA Therapeutics with a buyout option. It is now declining that option.
Ziopharm Oncology’s executive vice president of R&D, Francois Lebel, M.D., is moving to cancer drugmaker Spectrum Pharmaceuticals effective Nov. 5.
CuraSen Therapeutics has pulled off a $54.5 million series A funding round as it gains big-name backing to help tackle neurodegenerative disorders.
Four years ago, J&J splashed out $1.75 billion to take control of antiviral firm Alios, but the lead drug from that deal now seems to be in trouble.
The planned clinical trial will test Gilead’s TLR7 agonist in combination with Aelix’s T-cell vaccine.
